Smart Takes

The Morning Briefing: Pharmaceutical patents

The Morning Briefing: Pharmaceutical patents

Posting in Healthcare

"The Morning Briefing" is SmartPlanet's daily roundup of must-reads from the web. This morning we're reading about pharmaceutical patents.

"The Morning Briefing" is SmartPlanet's daily roundup of must-reads from the web. This morning we're reading about pharmaceutical patents.

1.) Drug patent issue too sensitive for trade negotiations. Europe's demand that Canada expand the patent rights of brand-name drug manufacturers has been deemed too politically hot for officials to handle in the Canada-European Union free trade negotiations, according to observers who have been briefed on the talks.

2.) Novartis patent case in India seen as crucial for generic drugs. The Indian Supreme Court is scheduled Wednesday to take up a case that aid agencies warn could have sweeping effects on the price of medicine for the global poor.

3.) Pfizer settles Impax patent suit over copy of drug Detrol. Pfizer Inc., the world's biggest drugmaker, settled a patent lawsuit over the application by Impax Laboratories Inc. to sell a copy of the bladder-control treatment Detrol LA.

4.) Coupons for brand-name medicines aim to keep people off generic drugs. If brand-name prescription medicines cost you as little as generic pills, which would you choose? A few drugmakers are betting Americans will stick with the name they know.

5.) FTC to court: Pay-for-delay drug deals unfair. Agreements in which the maker of a brand name drug promises a patent challenger, it will not launch a competing authorized generic are anti-competitive and should be stopped, the Federal Trade Commission (FTC) told a federal court.

Image credit: Flickr

Related:

Share this

Charlie Osborne

Contributing Editor

Charlie Osborne is a freelance journalist and photographer based in London. In addition to SmartPlanet, she also writes for business technology website ZDNet and consumer technology site CNET. She holds a degree in medical anthropology from the University of Kent. Follow her on Twitter. Disclosure